The Journal of Bone and Joint Surgery (American). 2009;91:274-281.
doi:10.2106/JBJS.G.01193
© 2009 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activities for this article:
 Adult Hip Reconstruction Test 32: Spring 2009 (publication date May 15, 200...
CME 1: January, February, March 2009 (publication date April 3, 2009; expir...
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedl, G.
Right arrow Articles by Windhager, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Friedl, G.
Right arrow Articles by Windhager, R.
Related Collections
Right arrow Adult Hip
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

The Effect of a Single Infusion of Zoledronic Acid on Early Implant Migration in Total Hip Arthroplasty

A Randomized, Double-Blind, Controlled Trial

Gerald Friedl, MD1, Roman Radl, MD1, Christoph Stihsen, MD1, Peter Rehak, PhD1, Reingard Aigner, MD1 and Reinhard Windhager, MD1

1 University Clinic of Orthopaedic Surgery (G.F., R.R., C.S., and R.W.), Department of Surgery, Unit for Biomedical Engineering and Computing (P.R.), and Division of Nuclear Medicine, Department of Radiology (R.A.), Medical University of Graz, AT-8036 Graz, Austria. E-mail address for G. Friedl: gerald.friedl{at}medunigraz.at. E-mail address for R. Radl: roman.radl{at}medunigraz.at. E-mail address for C. Stihsen: christoph_sti{at}gmx.at. E-mail address for P. Rehak: peter.rehak{at}medunigraz.at. E-mail address for R. Aigner: reingard.aigner{at}medunigraz.at. E-mail address for R. Windhager: reinhard.windhager{at}medunigraz.at

Investigation performed at the Medical University of Graz, Graz, Austria

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. One or more of the authors or a member of his or her immediate family received, in any one year, payments or other benefits in excess of $10,000 or a commitment or agreement to provide such benefits from commercial entitities (DePuy Orthopaedics and Orthovita). Also, a commercial entity (DePuy Orthopaedics) paid or directed in any one year, or agreed to pay or direct, benefits in excess of $10,000 to a research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which one or more of the authors, or a member of his or her immediate family, is affiliated or associated.

A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM/DVD (call our subscription department, at 781-449-9780, to order the CD-ROM or DVD).

Background: Aseptic loosening is the most frequent cause of implant failure in total hip arthroplasty. While a direct link between aseptic loosening and periprosthetic bone loss remains elusive, there is plentiful evidence for a close association with early implant migration. The present trial was primarily designed to evaluate whether a single infusion of 4 mg of zoledronic acid prevented early implant migration in patients with osteonecrosis of the femoral head.

Methods: Fifty patients were consecutively enrolled to receive either zoledronic acid or saline solution after cementless total hip arthroplasty. Radiographs, biochemical parameters of bone turnover, and the Harris hip-rating score were determined preoperatively and at each follow-up examination at seven weeks, six months, one year, and yearly thereafter. The median follow-up period was 2.8 years.

Results: We found a significant subsidence of the stem of up to a mean (and standard deviation) of –1.2 ± 0.6 mm at two years within the control group, and the cups had a mean medialization of 0.6 ± 1.0 mm and a mean cranialization of 0.6 ± 0.8 mm (p < 0.001). Treatment with zoledronic acid effectively minimized the migration of the cups in both the transverse and the vertical direction (mean, 0.15 ± 0.6 mm and 0.06 ± 0.6 mm, respectively; p < 0.05), while only a trend to decreased subsidence of the stem was detected. Finally, the Harris hip score rapidly increased over time in both treatment groups, although this increase was significantly more pronounced in the zoledronate-treated group than in the control group (analysis of variance, p = 0.008).

Conclusions: A single infusion of zoledronic acid shows promise in improving initial fixation of a cementless implant, which may improve the clinical outcome of total hip arthroplasty in patients with osteonecrosis of the femoral head.

Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?